Nimble Diagnostics secures a €2.5 million grant from the EIC Accelerator programme

- Innovation

Nimble Diagnostics has been awarded a €2.5 million grant from EIC Accelerator, a funding programme of the European Innovation Council and SMEs Executive Agency (EISMEA). This spin-off from the Germans Trias i Pujol Research Institute (IGTP), the Polytechnic University of Catalonia - BarcelonaTech (UPC) and the University of Barcelona (UB), is among the 47 selected companies from 15 countries, chosen from a pool of 648 proposals.

Nimble Diagnostics' selection for this grant reflects its potential in the MedTech field. The funding will help the company to develop non-invasive diagnostic technologies to support cardiovascular patients and clinicians and perform its first European clinical trial.

The company's management team, including CEO Dr Oriol Iborra Egea, CTO Susana Amorós Garcia de Valdecasas, and COO Andrés Ortega-Verdaguer, played a key role in securing the funding, which is part of the European Commission's initiative to support MedTech startups. In this case, the grant is part of the programme EIC Accelerator, which aims to support innovative companies across Europe.

The co-founder and board member of Nimble Diagnostics, Dr Oriol Iborra Egea, commented on this achievement: "This recognition fuels our commitment to continue working hard in developing our novel technology that could help millions of patients each year. This grant will allow us to consolidate and expand our team, finish prototyping and perform our first clinical trial in Europe. We are really excited for our future, and I could not be prouder of our team and partners that have helped us getting here."

Nimble Diagnostics and Oriol Iborra received the Best SITE Innovation Award

On 7 October, both Nimble Diagnostics and Dr Iborra Egea received the award as the best innovation in endovascular cardiology at the 23rd international symposium SITE Congress 2023, celebrated in Barcelona.

This recognition by the international Endovascular Foundation reinforces NIMBLE Diagnostics' commitment to continue working to bring its novel technology to cardiovascular patients, saving lives, and making the healthcare system more sustainable.